Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...

LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...

Thousands of men with prostate cancer will be offered a life-extending drug on the NHS within weeks. For the first time patients whose prostate cancer has not spread will be able to receive the drug ...

The phase three clinical trial reached a milestone with its first American participant receiving treatment, advancing ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...